Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal
NCT ID: NCT04906941
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
73 participants
OBSERVATIONAL
2022-01-21
2023-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Évaluation de l'Impact du Compressed Sensing Sur le Signal QSM
NCT04907487
Performance Evaluation of a 3D PSIR Sequence in MRI at 1.5T
NCT04707144
Evaluation of New MRI Sequences Including 3D-FGAPSIR for the Optimization of Inflammatory Spinal Cord Lesions Research
NCT04906928
Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis
NCT04705870
MRI Exploration of Meningeal Inflammatory Disease
NCT04707170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.
\* Sense 2 \* 2: 9min33s
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with an inflammatory CNS pathology
* to benefit as part of care from an MRI with injection of gadolinium
* consent to participate in the study
* beneficiary of a social protection scheme
Exclusion Criteria
* patient benefiting from a legal protection measure
* Patient having performed more than 3 MRI exams with gadolinium injection during his life
* motion artifact not allowing image interpretation
* patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection.
Secondarily excluded patients will be replaced up to a maximum of 25 patients.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hhopital fondation adolphe de rothschild
Paris, Paris, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSY_2021_14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.